1. Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia. (September 2022) Authors: Zacholski, Kyle; Hambley, Bryan; Hickey, Erin; Kashanian, Sarah; Li, Andrew; Baer, Maria R; Duong, Vu H; Newman, Matthew J; DeZern, Amy; Gojo, Ivana; Smith, B Douglas; Levis, Mark J; Varadhan, Ravi; Gehrie, Eric; Emadi, Ashkan; Ghiaur, Gabriel Journal: Journal of oncology pharmacy practice Issue: Volume 28:Number 6(2022) Page Start: 1340 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. (August 2015) Authors: Zeidan, Amer M; Hendrick, Franklin; Friedmann, Erika; Baer, Maria R; Gore, Steven D; Sasane, Medha; Paley, Carole; Davidoff, Amy J Journal: Journal of comparative effectiveness research Issue: Volume 4:Number 4(2015) Page Start: 327 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. (August 2015) Authors: Zeidan, Amer M; Hendrick, Franklin; Friedmann, Erika; Baer, Maria R; Gore, Steven D; Sasane, Medha; Paley, Carole; Davidoff, Amy J Journal: Journal of comparative effectiveness research Issue: Volume 4:Number 4(2015) Page Start: 327 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Effects of Toll-like receptor signals in T-cell neoplasms. (February 2011) Authors: Morrison, Cori; Baer, Maria R; Zandberg, Dan P; Kimball, Amy; Davila, Eduardo Journal: Future oncology Issue: Volume 7:Number 2(2011) Page Start: 309 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effects of Toll-like receptor signals in T-cell neoplasms. (February 2011) Authors: Morrison, Cori; Baer, Maria R; Zandberg, Dan P; Kimball, Amy; Davila, Eduardo Journal: Future oncology Issue: Volume 7:Number 2(2011) Page Start: 309 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Issue 10299 (7th August 2021) Authors: Shah, Bijal D; Ghobadi, Armin; Oluwole, Olalekan O; Logan, Aaron C; Boissel, Nicolas; Cassaday, Ryan D; Leguay, Thibaut; Bishop, Michael R; Topp, Max S; Tzachanis, Dimitrios; O'Dwyer, Kristen M; Arellano, Martha L; Lin, Yi; Baer, Maria R; Schiller, Gary J; Park, Jae H; Subklewe, Marion; Abedi, Me... Journal: Lancet Issue: Volume 398:Issue 10299(2021) Page Start: 491 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Issue 1 (January 2023) Authors: Watts, Justin M; Baer, Maria R; Yang, Jay; Prebet, Thomas; Lee, Sangmin; Schiller, Gary J; Dinner, Shira N; Pigneux, Arnaud; Montesinos, Pau; Wang, Eunice S; Seiter, Karen P; Wei, Andrew H; De Botton, Stephane; Arnan, Montserrat; Donnellan, Will; Schwarer, Anthony P; Récher, Christian; Jonas, Bri... Journal: Lancet Issue: Volume 10:Issue 1(2023) Page Start: e46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management. (January 2020) Authors: Bade, Najeebah A; Lu, Crystal; Patzke, Ciera L; Baer, Maria R; Duong, Vu H; Law, Jennie Y; Lee, Seung T; Sausville, Edward A; Zimrin, Ann B; Duffy, Alison P; Lawson, Justin; Emadi, Ashkan Journal: Journal of oncology pharmacy practice Issue: Volume 26:Number 1(2020) Page Start: 74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Issue 4 (April 2016) Authors: Garcia-Manero, Guillermo; Fenaux, Pierre; Al-Kali, Aref; Baer, Maria R; Sekeres, Mikkael A; Roboz, Gail J; Gaidano, Gianluca; Scott, Bart L; Greenberg, Peter; Platzbecker, Uwe; Steensma, David P; Kambhampati, Suman; Kreuzer, Karl-Anton; Godley, Lucy A; Atallah, Ehab; Collins, Robert; Kantarjian, ... Journal: Lancet oncology Issue: Volume 17:Issue 4(2016:Apr.) Page Start: 496 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Issue 8 (August 2017) Authors: Perl, Alexander E; Altman, Jessica K; Cortes, Jorge; Smith, Catherine; Litzow, Mark; Baer, Maria R; Claxton, David; Erba, Harry P; Gill, Stan; Goldberg, Stuart; Jurcic, Joseph G; Larson, Richard A; Liu, Chaofeng; Ritchie, Ellen; Schiller, Gary; Spira, Alexander I; Strickland, Stephen A; Tibes, Ra... Journal: Lancet oncology Issue: Volume 18:Issue 8(2017:Aug.) Page Start: 1061 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗